AstraZeneca (AZN) Set to Announce Earnings on Friday

AstraZeneca (NASDAQ:AZNGet Rating) is scheduled to be releasing its earnings data before the market opens on Friday, April 29th. Analysts expect AstraZeneca to post earnings of $0.87 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

AstraZeneca (NASDAQ:AZNGet Rating) last released its quarterly earnings data on Thursday, February 10th. The company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.07. AstraZeneca had a net margin of 0.30% and a return on equity of 27.48%. The business had revenue of $11.50 billion for the quarter, compared to analyst estimates of $11.06 billion. During the same quarter last year, the firm earned $0.54 EPS. AstraZeneca’s quarterly revenue was up 55.2% compared to the same quarter last year. On average, analysts expect AstraZeneca to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Shares of AZN stock opened at $67.39 on Friday. The firm has a fifty day moving average of $63.79 and a 200-day moving average of $60.35. The company has a quick ratio of 0.76, a current ratio of 1.16 and a debt-to-equity ratio of 0.72. AstraZeneca has a 12-month low of $50.66 and a 12-month high of $71.70. The company has a market capitalization of $208.83 billion, a price-to-earnings ratio of 481.39, a P/E/G ratio of 1.30 and a beta of 0.48.

The firm also recently announced a semi-annual dividend, which was paid on Monday, March 28th. Investors of record on Friday, February 25th were issued a dividend of $0.985 per share. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.45. The ex-dividend date was Thursday, February 24th. This represents a yield of 2.4%. AstraZeneca’s dividend payout ratio is presently 1,378.67%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zullo Investment Group Inc. acquired a new position in shares of AstraZeneca in the 4th quarter valued at approximately $28,000. Carroll Investors Inc bought a new position in AstraZeneca in the 4th quarter valued at about $33,000. NEXT Financial Group Inc grew its position in AstraZeneca by 90.4% in the 4th quarter. NEXT Financial Group Inc now owns 1,864 shares of the company’s stock valued at $109,000 after buying an additional 885 shares in the last quarter. Salem Investment Counselors Inc. grew its position in AstraZeneca by 183.9% in the 4th quarter. Salem Investment Counselors Inc. now owns 2,839 shares of the company’s stock valued at $165,000 after buying an additional 1,839 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its stake in AstraZeneca by 8.2% during the fourth quarter. CWA Asset Management Group LLC now owns 3,933 shares of the company’s stock valued at $229,000 after purchasing an additional 297 shares during the last quarter. 20.54% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have commented on AZN. SVB Leerink raised their target price on shares of AstraZeneca from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, February 24th. JPMorgan Chase & Co. lifted their price objective on shares of AstraZeneca from £100 ($130.11) to £120 ($156.13) in a research note on Thursday, April 7th. Deutsche Bank Aktiengesellschaft upped their target price on shares of AstraZeneca from £105 ($136.61) to £115 ($149.62) in a research note on Wednesday, April 6th. Barclays upped their price objective on shares of AstraZeneca from £115 ($149.62) to £120 ($156.13) in a report on Thursday, April 14th. Finally, Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating and set a $61.00 price objective on the stock in a research report on Tuesday, January 4th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, AstraZeneca has an average rating of “Buy” and an average price target of $7,223.13.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Earnings History for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.